亿帆医药子公司亿帆制药签署关于一项创新药独家协议

Group 1 - The core point of the news is that Yifan Pharmaceutical has signed exclusive agreements with Shangde Yaoyuan and Tianjin Shangde to obtain exclusive rights for the drug ACT001, which is a novel mechanism Class 1 innovative drug targeting small cell lung cancer brain metastasis [1][2] - Yifan Pharmaceutical will pay a total of 1 billion yuan as an upfront payment, with options for additional payments based on milestones or sales revenue sharing [1] - The drug ACT001 has undergone multiple clinical trials in China, the US, and Australia over the past eight years, and has received "breakthrough therapy" designation from the National Medical Products Administration for its indication in small cell lung cancer brain metastasis [2] Group 2 - ACT001 works by inhibiting the NF-κB and STAT3 signaling pathways in the tumor microenvironment, which reduces the DNA repair capability of tumor cells and enhances the effects of chemotherapy and immunotherapy [2] - The introduction of ACT001 is expected to effectively supplement Yifan Pharmaceutical's oncology pipeline while avoiding the high costs and time associated with developing new drugs from scratch [2]